Stockscreener 앱 받기
5.83
0.17%
0.010
시간 외 거래:
5.85
0.02
+0.34%
전일 마감가:
$5.82
열려 있는:
$5.77
하루 거래량:
199.12K
Relative Volume:
0.59
시가총액:
$467.59M
수익:
$351.37M
순이익/손실:
$-169.52M
주가수익비율:
-2.7452
EPS:
-2.1237
순현금흐름:
$-147.86M
1주 성능:
+8.77%
1개월 성능:
+24.04%
6개월 성능:
+17.07%
1년 성능:
+75.08%
1일 변동 폭
$5.76
$5.90
1주일 범위
$5.31
$5.90
52주 변동 폭
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
명칭
Atea Pharmaceuticals Inc
전화
(857) 284-8891
주소
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
5.83 | 429.90M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-10-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 개시 | Evercore ISI | Outperform |
| 2020-11-24 | 개시 | JP Morgan | Overweight |
| 2020-11-24 | 개시 | Morgan Stanley | Overweight |
| 2020-11-24 | 개시 | William Blair | Outperform |
모두보기
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating - marketscreener.com
Atea Pharmaceuticals (AVIR.US) will release its earnings report after market close on August 12. - Moomoo
AVIR Holds Steady Near $5.06 as Atea Pharmaceuticals Tests Key Technical LevelsTime Weighted Price - vinanet.vn
Atea Pharmaceuticals, Inc. (AVIR) stock price, news, quote and history - Yahoo Finance UK
Atea Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Atea Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-08-12 - Seeking Alpha
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing - Kalkine Media
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Atea beats Q2 2026 EPS view but shares fall after hours - Investing.com
ATEA PHARMACEUTICALS ($AVIR) Releases Q2 2026 Earnings - Quiver Quantitative
Atea Pharmaceuticals (NASDAQ: AVIR) advances HCV Phase 3 as losses widen - Stock Titan
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Atea Hepatitis C Regimen Posts 93.9% Sustained Response - Stock Titan
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a shareEarnings Preview - TradingView
AVIR Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Up 5.2%Profit Cycle Analysis - Vinanet
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks - webull.com
Arrowstreet Capital Limited Partnership Takes Position in Atea Pharmaceuticals, Inc. $AVIR - MarketBeat
Atea's Aug. 12 webcast will include a business update - Stock Titan
Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Thursday - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Yahoo Finance
Atea posts late-stage trial win for hepatitis C drug (AVIR) - Seeking Alpha
Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus - marketscreener.com
Atea’s hepatitis C drug meets primary endpoint in phase 3 trial - Investing.com Canada
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus - GlobeNewswire
AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus - European AIDS Treatment Group
Atea Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AVIR - TradingView
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Cash Flow - TradingKey
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atea Pharmaceuticals (AVIR) Edges Lower Amid Light Trading; Key Support Levels in FocusPCR Extreme - vinanet.vn
BML Capital Management LLC Sells 431,343 Shares of Atea Pharmaceuticals, Inc. $AVIR - MarketBeat
Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy - TipRanks
Atea Pharmaceuticals (AVIR) Faces Modest Decline Near Key Support LevelIchimoku Kumo Twist - dars.gov.et
Atea Pharmaceuticals Starts Phase 1 AT-587 Trial - t.co
Atea Pharmaceuticals (AVIR) Gains 3.4% – Biotech Momentum Tests Key ResistanceATR Trailing Stop - dars.gov.et
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating - Moomoo
Atea begins phase 1 trial of hepatitis E treatment AT-587 - Investing.com UK
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
Atea Pharmaceuticals initiates Phase 1 trial for AT-587 - scanx.trade
Atea Pharmaceuticals Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesGuidance Accuracy Score - vinanet.vn
AVIR Q1 2026 Earnings: Narrower-than-expected Loss Drives Modest Stock GainCost Structure Review - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Atea Pharmaceuticals Inc (AVIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atea Pharmaceuticals Inc 주식 (AVIR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
536,097 |
| DUNCAN BARBARA GAYLE | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Polsky Bruce | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
124,806 |
| Murphy Polly A. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
121,745 |
| Adams Jerome M. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Corcoran Andrea | See Remarks |
Mar 11 '26 |
Option Exercise |
1.24 |
60,000 |
74,400 |
823,576 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
0.86%
0.31%
자본화:
|
볼륨(24시간):